Show simple item record

dc.contributor.authorBeeton, Michael L.
dc.contributor.authorZhang, Xu-Sheng
dc.contributor.authorUldum, Søren A.
dc.contributor.authorBébéar, Cécile
dc.contributor.authorDumke, Roger
dc.contributor.authorGullsby, Karolina
dc.contributor.authorIeven, Margareta
dc.contributor.authorLoens, Katherine
dc.contributor.authorNir-Paz, Ran
dc.contributor.authorPereyre, Sabine
dc.contributor.authorSpiller, O. Brad
dc.contributor.authorChalker, Victoria J.
dc.contributor.authorESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae sub-group
dc.date.accessioned2019-07-23T15:29:07Z
dc.date.available2019-07-23T15:29:07Z
dc.date.issued2020-01-16
dc.identifier.citationBeeton, M.L., Zhang, X.S., Uldum, S.A., Bébéar, C., Dumke, R., Gullsby, K., Ieven, M., Loens, K., Nir-Paz, R., Pereyre, S. and Spiller, O.B. (2020) 'Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016', Eurosurveillance, 25(2), p.1900112.
dc.identifier.issn1560-7917
dc.identifier.issn1025-496X (online)
dc.identifier.urihttp://hdl.handle.net/10369/10638
dc.descriptionArticle published in Eurosurveillance on 16 January 2020 (online), available open access at: https://doi.org/10.2807/1560-7917.ES.2020.25.2.1900112.en_US
dc.description.abstractBackground: Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia, with large epidemics previously described to occur every 4 to 7 years. Aim: To better understand the diagnostic methods used to detect M. pneumoniae; to better understand M. pneumoniae testing and surveillance in use; to identify epidemics; to determine detection number per age group, age demographics for positive detections, concurrence of epidemics and annual peaks across geographical areas; and to determine the effect of geographical location on the timing of epidemics. Methods: A questionnaire was sent in May 2016 to Mycoplasma experts with national or regional responsibility within the ESCMID Study Group for Mycoplasma and Chlamydia Infections in 17 countries across Europe and Israel, retrospectively requesting details on M. pneumoniae-positive samples from January 2011 to April 2016. The Moving Epidemic Method was used to determine epidemic periods and effect of country latitude across the countries for the five periods under investigation. Results: Representatives from 12 countries provided data on M. pneumoniae infections, accounting for 95,666 positive samples. Two laboratories initiated routine macrolide resistance testing since 2013. Between 2011 and 2016, three epidemics were identified: 2011/12, 2014/15 and 2015/16. The distribution of patient ages for M. pneumoniae-positive samples showed three patterns. During epidemic years, an association between country latitude and calendar week when epidemic periods began was noted. Conclusions: An association between epidemics and latitude was observed. Differences were noted in the age distribution of positive cases and detection methods used and practice. A lack of macrolide resistance monitoring was noted.en_US
dc.language.isoenen_US
dc.publisherEuropean Centre for Disease Prevention and Controlen_US
dc.relation.ispartofseriesEurosurveillance;
dc.titleMycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016en_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.2807/1560-7917.ES.2020.25.2.1900112
dcterms.dateAccepted2019-07-15
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionAMen_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en_US
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record